Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology

 Astellas Signs a Research and License Agreement with Xencor for  Bispecific Antibody Program in Oncology

Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology

Shots:

  • Xencor to receive an upfront, development, regulatory & commercialization milestones and royalties on sales of product. Astellas to get exclusive WW license to develop and commercialize bispecific mAb for cancer
  • Xencor to utilize its XmAb technology for the development of bispecific Ab candidates against Astellas’ targets & will take care of initial characterization of molecules. Astellas will be responsible for all preclinical, clinical, development, regulatory and commercial activities
  • Xencor’s XmAb technology consists of Fc domains enabling Abs to bind two or more targets with changes in the structure of mAb resulting novel therapies for cancer  

Click here to read full press release/ article | Ref: Xencor | Image: Student Show

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post